AdaptHealth reported $132 million in adjusted EBITDA for Q2 2026. On a GAAP basis, the Company posted a loss of $0.99 per share. Levi & Korsinsky is investigating potential securities law violations on behalf of AHCO investors who lost money
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) — AdaptHealth Corp. (NASDAQ: AHCO) shareholders watched as much as 26% of their investment disappear after the Company’s Q2 2026 results showed a GAAP loss of $0.99 per share — against roughly $0.15 of profit expected. If you lost money on AHCO, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
AdaptHealth reported adjusted EBITDA of $132 million for Q2 2026. The GAAP bottom line told a different story: a $0.99 per-share loss, as the Company simultaneously reduced its full-year 2026 revenue and adjusted EBITDA outlook.
Shareholders who purchased AHCO and suffered losses may request a free case evaluation here or call (212) 363-7500.
Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the AHCO Investigation
Q: How much did AHCO stock drop? A: Shares fell as much as 26% after AdaptHealth reported a GAAP loss of $0.99 per share alongside $132 million of adjusted EBITDA and a $144.2 million goodwill impairment charge. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether AdaptHealth Corp. made materially false or misleading statements regarding its full-year 2026 revenue and adjusted EBITDA outlook. Less than three months later, the Company reset 2026 revenue guidance to approximately $2.85 billion to $2.89 billion and the stock price declined sharply.
Q: Who is eligible to participate in the AHCO investigation? A: Investors who purchased AHCO stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: What do AHCO investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my AHCO shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AHCO and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost. Securities investigations and any resulting actions are generally handled on a contingency basis — no retainer and no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
